Consequently, the present study was undertaken to assess the in vitro effect of SRA737 on pairs of NSCLC (A549 & H23) and CRC (HCT116 & HT29) cancer cell lines, with each pair processing a cell line with MUT TP53 [H23: bearing a mutation at codon 246 (C → G; Ile → Met); HT29: bearing a mutation at codon 273 (G → A; Arg → His)]. This evidence concerns the gene TP53 and colorectal carcinoma.